Labomar Logo

Labomar

LBM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005421646
LEI:
815600BD66DA7878FF03
Country:
Italy
Address:
VIA NAZARIO SAURO, 35/I, 31036 ISTRANA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Labomar is a full-service Contract Development and Manufacturing Organization (CDMO) founded in 1998. The company specializes in the research, development, and production of nutraceuticals, food supplements, medical devices, foods for special medical purposes, and cosmetics for third-party clients. Operating as an innovation-driven B2B partner, Labomar offers a 'one-stop-shop' service, from product conception to finished goods. It leverages patented and state-of-the-art technologies to create high-quality, bespoke solutions in various pharmaceutical forms. The company also provides personalized advice on key European industry directives and regulations. As a certified B Corporation, Labomar is committed to creating safe and effective products that enhance personal wellbeing.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Labomar. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-09-06 14:28
Delisting Announcement
Comunicato Procedura congiunta e revoca
Italian 282.1 KB
2023-08-31 19:53
M&A Activity
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 282.5 KB
2023-08-29 17:19
Delisting Announcement
Comunicato Risultati Definitivi Sell-Out
Italian 300.3 KB
2023-08-28 17:56
Delisting Announcement
Comunicato Risultati Provvisori Sell-Out
Italian 301.7 KB
2023-08-25 17:56
M&A Activity
Comunicato adesioni Sell-Out terza settimana
Italian 302.1 KB
2023-08-18 18:16
Related Party Transaction
Comunicato Adesioni Sell Out Seconda Settimana
Italian 300.8 KB
2023-08-11 18:04
Delisting Announcement
Comunicato adesioni Sell-Out prima settimana
Italian 303.6 KB
2023-08-04 23:17
M&A Activity
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 687.4 KB
2023-08-04 20:09
Major Shareholding Notification
Comunicato Azionista Significativo LBM Next S.p.A.
Italian 398.1 KB
2023-08-04 20:07
Major Shareholding Notification
Comunicato Azionista Significativo_conferimento LBM Holding
Italian 397.5 KB
2023-08-04 20:06
Major Shareholding Notification
Comunicato Azionista Significativo_Master Lab
Italian 398.3 KB
2023-08-04 20:03
Major Shareholding Notification
Comunicato Azionista Significativo_CCP
Italian 396.9 KB
2023-08-02 19:34
M&A Activity
Comunicato risultati OPA definitivi
Italian 783.8 KB
2023-08-01 18:07
Related Party Transaction
Comunicato ex art. 41, comma 2, lett. c) RE
Italian 285.3 KB
2023-07-31 18:53
M&A Activity
Comunicato risultati OPA provvisori
Italian 308.4 KB

Automate Your Workflow. Get a real-time feed of all Labomar filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Labomar via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ObsEva SA Logo
Developed therapeutics for women's reproductive health and pregnancy; now winding down operations.
Switzerland OBSN
ODI Pharma AB Logo
Produces and distributes pharmaceutical-grade medicinal cannabis products across Europe.
Sweden ODI
Oncolys BioPharma Inc. Logo Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
OncoTherapy Science, Inc. Logo Japan 4564
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
Orexo Logo
Develops pharmaceuticals for opioid use disorder and pain using innovative drug delivery technology.
Sweden ORX
Orion Oyj Logo
Develops and markets human/vet pharmaceuticals and APIs, focusing on oncology and pain management.
Finland ORNAV